Oncology drugs

lilyo's version from 2016-06-02 04:31


Question Answer
Cisplatin, carboplatincross-link DNA
Etoposide, teniposideetoposide inhibits topoisomerase II --> increased DNA degradation
Irinotecan, topotecaninhibit topoisomerase I and prevent DNA unwinding and replication
Hydroxyureainhibits ribonucleotide reductase --> decreased DNA synthesis (S-phase specific)
prednisone, prednisolonebind intracytoplasmic steroid receptor, alter gene transcription
bevacixumabmonoclonal antibody against VEGF, inhibits angiogenesis
erlotinibEGFR tyrosine kinase inhibitor
Cetuximabmonoclonal antibody against EGFR
imatinibtyrosine kinase inhibitor of BCR-ABL and c-kit
rituximabmonoclonal antibody against CD20
tamoxifen, raloxifenselective estrogen receptor modulators (receptor antagonists in breast and agonists in bone)
trastuzumabmonoclonal antibody against HER-2, a tyrosine kinase inhibitor
vemurafenibsmall molecule inhibitor of BRAF oncogene + melanoma
paclitaxelhyperstabilize polymerized microtubules in M phase so that mitotic spindle cannot break down (anaphase cannot occur)
vincristine, vinblastinebind beta-tubulin and inhibit its polymerization into microtubules --> prevent mitotic spindle formation
busulfancross-links DNA
cyclophosphamide, ifosfamidecross-link DNA at guanine N-7, require bioactivation by liver
nitrosureas (carmustine, lomustine, semustine, streptozocin)require bioactivation, cross BBB --> CNS, cross-link DNA
bleomycininduces free radical formation --> breaks in DNA strands
dactinomycinintercalates in DNA
doxorubicin, daunorubicingenerate free radicals, intercalate in DNA